Under the partnership, Goldfinch is tasked with sequencing the DNA of diabetic patients with and without kidney disease and using that information to expand its Kidney Genome Atlas, a registry comprising both clinical patient profiles and genomic, transcriptomic and proteomic data, to allow analysis of diabetic kidney disease.
From there, Goldfinch will study pluripotent stem cell-derived kidney cells and kidney organoids to identify potential drug targets, then begin the discovery and development process for those treatments.
Gilead will pay Goldfinch $55 million up front for the exclusive option rights to the startup’s drug discovery data, plus $54 million for the Kidney Genome Atlas expansion. Goldfinch will also be eligible to earn up to $1.95 billion more, depending on the success of its first five projects with Gilead.
More articles about health IT:
Spectrum Health Lakeland alerts 1,100 patients of data breach
PayPal considers blockchain but not sold on cryptocurrency
No experience needed for cybersecurity jobs
